Reduktion des kardiovaskulären Risikos bei Diabetes

Zusammenfassung

In industrialisierten Ländern ist der Lebensstil häufig durch einen Mangel körperlicher Bewegung sowie eine ungesunde Ernährung geprägt, welche den Boden für die Entstehung einer Adipositas liefern, deren Prävalenz kontinuierlich zunimmt. Hiermit einhergehend kommt es zu einer stetigen Zunahme der Diabetes-Inzidenz und einer hiermit einhergehenden akzelerierten Atherosklerose. Entsprechend stellt die Therapie von Übergewicht und Adipositas einen zentralen Ansatzpunkt in der Prävention des Diabetes dar. Darüber hinausgehend gelingt es, über eine multifaktorielle Therapie kardiovaskulärer Risikofaktoren wie Dyslipidämie, arteriellen Hypertonie und Hyperglykämie eine effektive Prävention mikro- und makrovaskulärer Komplikationen zu erreichen.

Abstract

The modern life style is often characterized by a lack of physical activity as well as unhealthy diet leading to a worldwide rise in obesity. This goes along with an increased incidence of type 2 diabetes, accompanied by an accelerated atherosclerosis. Life style changes and normalization of body weight therefore represent the cornerstones of diabetes prevention. In addition, a multi-factorial approach focusing on cardiovascular risk factors like dyslipidemia, hypertension and hyperglycemia enables an effective means for the prevention of micro- or macrovascular complications.

Schlüsselwörter

Diabetes mellitus - kardiovaskuläre Krankheiten - Typ-2-Diabetes

Key Words

diabetes mellitus - cardiovascular diseases - type 2 diabetes

• Literaturverzeichnis

• 1 Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-2038
• 2 Mascarenhas-Melo F, Marado D, Palavra F et al. Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. Cardiovasc Diabetol 2013; 12: 61
• 3 Wannamethee SG, Shaper AG, Whincup PH et al. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011; 171: 404-410
• 4 Seshasai SR, Kaptoge S, Thompson A et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841
• 5 Gregg EW, Li Y, Wang J et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 2014; 370: 1514-1523
• 6 Yeboah J, Erbel R, Delaney JC et al. Development of a new diabetes risk prediction tool for incident coronary heart disease events: The Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. Atherosclerosis 2014; 236: 411-417
• 7 Chan JM, Rimm EB, Colditz GA et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes care 1994; 17: 961-969
• 8 Hinnouho GM, Czernichow S, Dugravot A et al. Metabolically healthy obesity and the risk of cardio­vascular disease and type 2 diabetes: the Whitehall II cohort study. Eur Heart J 2015; 36: 551-559
• 9 Stefan N, Kantartzis K, Machann J et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616
• 10 Huang-Doran I, Sleigh A, Rochford JJ et al. Lipodystrophy: metabolic insights from a rare disorder. J Endocrinol 2010; 207: 245-255
• 11 Smith SR, De Jonge L, Volaufova J et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 2005; 54: 24-32
• 12 Zhao W, Katzmarzyk PT, Horswell R et al. Body Mass Index and the Risk of All-Cause Mortality Among Patients with Type 2 Diabetes. Circulation 2014; 130: 2143-2151
• 13 Wing RR, Bolin P, Brancati FL et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154
• 14 Sjostrom L, Peltonen M, Jacobson P et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65
• 15 Sjostrom L, Peltonen M, Jacobson P et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311: 2297-2304
• 16 Rucker D, Padwal R, Li SK et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199
• 17 Hauner H, Buchholz G, Hamann A et al. Adipositas und Diabetes mellitus. Diabetologie und Stoffwechsel 2013; 8: 103-240
• 18 Blazing MA, Giugliano RP, Cannon CP et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18, 144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J 2014; 168: 205-212 e201
• 19 Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014; 371: 32-41
• 20 Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117, 411 patients. BMJ 2014; 349: g4379
• 21 Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574
• 22 Chew EY, Ambrosius WT, Davis MD et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Eng J Med 2010; 363: 233-244
• 23 Landray MJ, Haynes R, Hopewell JC et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Eng J Med 2014; 371: 203-212
• 24 Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Eng J Med 2011; 365: 2255-2267
• 25 Rohatgi A, Khera A, Berry JD et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Eng J Med 2014; 371: 2383-2393
• 26 Lind M, Svensson AM, Kosiborod M et al. Glycemic control and excess mortality in type 1 diabetes. N Eng J Med 2014; 371: 1972-1982
• 27 Gerstein HC, Miller ME, Genuth S et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Eng J Med 2011; 364: 818-828
• 28 Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med 2008; 358: 2560-2572
• 29 Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Eng J Med 2009; 360: 129-139
• 30 Gerstein HC, Miller ME, Ismail-Beigi F et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 2014; 384: 1936-1941
• 31 Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298
• 32 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care 2012; 35: 1364-1379
• 33 Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Eng J Med 2008; 359: 1577-1589
• 34 Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Eng J Med 2005; 353: 2643-2653
• 35 Zoungas S, Chalmers J, Neal B, Billot L et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Eng J Med 2014; 371: 1392-1406